TFRC and cancer: This pathway was expected to lead to enhanced Ru(III) uptake by cancer cells that overexpress TfR1 [56] and selective activation of the drug in the hypoxic environment of solid tumors [57] that facilitate Ru(III) reduction to Ru(II) [54,55].